Two Nicotine Addiction Vaccines On Phase III Racetrack
Novartis partners with Cytos on CYT002-NicQb, while Nabi looks to partner NicVax prior to pivotal trials in second half.
Novartis partners with Cytos on CYT002-NicQb, while Nabi looks to partner NicVax prior to pivotal trials in second half.